Lesinidase alfa
- Generic Name
- Lesinidase alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1522433-40-4
- Unique Ingredient Identifier
- 61A4G0P3IB
- Background
Lesinidase alfa is under investigation in clinical trial NCT02324049 (Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)).
- Associated Conditions
- -
- Associated Therapies
- -
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02618512
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02324049
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath